KRTL Biotech Inc. Strengthens Import Operations with Official Customs Broker Appointment, Paving the Way for Global API Expansion
Press Release
OTC Disclosure & News Service | 07/31/2025
KRTL Holding Group Inc. (OTC: KRTL), through its wholly owned subsidiary KRTL Biotech Inc., proudly announces a pivotal milestone in its pharmaceutical logistics strategy: the official appointment and activation of its U.S. Customs Broker, Livingston International. This critical infrastructure upgrade enables seamless importation of Active Pharmaceutical Ingredients (APIs) and other pharmaceutical-grade products, significantly strengthening KRTL Biotech’s operational capabilities and global market access.
By securing Livingston International as its customs broker, KRTL Biotech is now positioned to streamline international procurement, simplify import compliance, and reduce delays across its pharmaceutical and nutraceutical supply chain. This advancement provides a clear pathway for efficiently scaling global trade operations and fortifying delivery pipelines for KRTL’s growing roster of international clients.
As a licensed U.S. Customs Broker, Livingston International brings to the table:
· Full-service import/export clearance for pharmaceutical goods, including those governed by the FDA and DEA.
· On-demand audit support and trade compliance consulting, aligning with CFR and USC requirements.
· Direct coordination with port authorities, customs officials, and regulatory bodies, ensuring uninterrupted entry and delivery of critical pharmaceutical imports.
This marks a new era of execution for KRTL Biotech, giving the company a competitive edge in servicing global pharmaceutical firms and reinforcing its growing reputation as a regulatory-compliant, logistics-ready solutions provider.
Rick Haxton, Global Sales Director of KRTL Biotech Inc., added, “This relationship doesn’t just serve our internal operations—it creates new opportunity for the clients we serve. From import-ready APIs to full product registration, we’re building a true turnkey model for pharmaceutical and nutraceutical companies entering the U.S. market.” In servicing global pharmaceutical firms and reinforcing its growing reputation as a regulatory-compliant, logistics-ready solutions provider.
The activation of customs brokerage services also empowers KRTL Biotech to serve additional clients across multiple sectors—from pharmaceutical brands seeking FDA-aligned importation to biotech researchers requiring exclusive molecule access. It demonstrates to the market that KRTL is prepared not just to source high-grade APIs, but to deliver them through a validated, compliant, and efficient infrastructure.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. (OTC: KRTL) operates through its wholly owned subsidiaries, KRTL Biotech Inc. and KRTL International Corp. The Company leverages strategic synergies across industries to pursue investments, mergers, and partnerships that deliver shareholder value. Focused on biotech, technology, and emerging market opportunities, KRTL Holding Group is committed to growth, innovation, and operational excellence.
About KRTL Biotech Inc.
KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group Inc., specializes in pharmaceutical registration, regulatory compliance, and FDA services for both international and domestic clients. The company plays a pivotal role in product registration and importation, ensuring seamless integration into the U.S. market. In addition, KRTL Biotech excels in client acquisition, sourcing exclusive APIs, and providing strategic regulatory guidance. Their innovative approach to navigating the complexities of pharmaceutical compliance and market entry positions them as a key driver of success for their partners and clients.
For more information:
www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com
Press Release
OTC Disclosure & News Service | 07/31/2025
KRTL Holding Group Inc. (OTC: KRTL), through its wholly owned subsidiary KRTL Biotech Inc., proudly announces a pivotal milestone in its pharmaceutical logistics strategy: the official appointment and activation of its U.S. Customs Broker, Livingston International. This critical infrastructure upgrade enables seamless importation of Active Pharmaceutical Ingredients (APIs) and other pharmaceutical-grade products, significantly strengthening KRTL Biotech’s operational capabilities and global market access.
By securing Livingston International as its customs broker, KRTL Biotech is now positioned to streamline international procurement, simplify import compliance, and reduce delays across its pharmaceutical and nutraceutical supply chain. This advancement provides a clear pathway for efficiently scaling global trade operations and fortifying delivery pipelines for KRTL’s growing roster of international clients.
As a licensed U.S. Customs Broker, Livingston International brings to the table:
· Full-service import/export clearance for pharmaceutical goods, including those governed by the FDA and DEA.
· On-demand audit support and trade compliance consulting, aligning with CFR and USC requirements.
· Direct coordination with port authorities, customs officials, and regulatory bodies, ensuring uninterrupted entry and delivery of critical pharmaceutical imports.
This marks a new era of execution for KRTL Biotech, giving the company a competitive edge in servicing global pharmaceutical firms and reinforcing its growing reputation as a regulatory-compliant, logistics-ready solutions provider.
Rick Haxton, Global Sales Director of KRTL Biotech Inc., added, “This relationship doesn’t just serve our internal operations—it creates new opportunity for the clients we serve. From import-ready APIs to full product registration, we’re building a true turnkey model for pharmaceutical and nutraceutical companies entering the U.S. market.” In servicing global pharmaceutical firms and reinforcing its growing reputation as a regulatory-compliant, logistics-ready solutions provider.
The activation of customs brokerage services also empowers KRTL Biotech to serve additional clients across multiple sectors—from pharmaceutical brands seeking FDA-aligned importation to biotech researchers requiring exclusive molecule access. It demonstrates to the market that KRTL is prepared not just to source high-grade APIs, but to deliver them through a validated, compliant, and efficient infrastructure.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. (OTC: KRTL) operates through its wholly owned subsidiaries, KRTL Biotech Inc. and KRTL International Corp. The Company leverages strategic synergies across industries to pursue investments, mergers, and partnerships that deliver shareholder value. Focused on biotech, technology, and emerging market opportunities, KRTL Holding Group is committed to growth, innovation, and operational excellence.
About KRTL Biotech Inc.
KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group Inc., specializes in pharmaceutical registration, regulatory compliance, and FDA services for both international and domestic clients. The company plays a pivotal role in product registration and importation, ensuring seamless integration into the U.S. market. In addition, KRTL Biotech excels in client acquisition, sourcing exclusive APIs, and providing strategic regulatory guidance. Their innovative approach to navigating the complexities of pharmaceutical compliance and market entry positions them as a key driver of success for their partners and clients.
For more information:
www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com
